[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.112.177. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 1987

Potential of Topical Norfloxacin TherapyComparative In Vitro Activity Against Clinical Ocular Bacterial Isolates

Author Affiliations

From the R. M. Alden Research Laboratory, Santa Monica (Calif) Hospital Medical Center (Dr Goldstein and Mss Citron, Bendon, and Vagvolgyi); the Departments of Ophthalmology and Microbiology, Estelle Doheny Eye Foundation and Hospital (Dr Trousdale); and Los Angeles County-University of Southern California Medical Center (Dr Appleman), Los Angeles.

Arch Ophthalmol. 1987;105(7):991-994. doi:10.1001/archopht.1987.01060070135043
Abstract

• Norfloxacin, a new fluoroquinolone antibiotic related to nalidixic acid, was evaluated as a topical agent for clinical efficacy in bacterial eye infections. This study reports on the comparative in vitro activity of norfloxacin and ten topical antibiotics (nalidixic acid, polymyxin B, colistin, bacitracin, chloramphenicol, sulfamethoxazole, tetracycline, erythromycin, gentamicin, and tobramycin) against 203 pathogenic eye isolates of 17 genera (37 species). In general, norfloxacin had the greatest potency and broadest spectrum of activity of the agents tested. It was active against Staphylococcus aureus (minimal inhibitory concentration against 90% [MIC90], ≤ 1.0 μg/mL), coagulase-negative staphylococci (MIC90, ≤1.0 μg/mL), Pseudomonas aeruginosa (MIC90, ≤1.0 μg/mL), and Haemophilus organisms (MIC90, ≤1.0 μg/mL).

×